These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12865568)

  • 1. Indian kala-azar--better tools needed for diagnosis and treatment.
    Sundar S
    J Postgrad Med; 2003; 49(1):29-30. PubMed ID: 12865568
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.
    Sundar S; Mondal D; Rijal S; Bhattacharya S; Ghalib H; Kroeger A; Boelaert M; Desjeux P; Richter-Airijoki H; Harms G
    Trop Med Int Health; 2008 Jan; 13(1):2-5. PubMed ID: 18290995
    [No Abstract]   [Full Text] [Related]  

  • 4. Availability of miltefosine for the treatment of kala-azar in India.
    Sundar S; Murray HW
    Bull World Health Organ; 2005 May; 83(5):394-5. PubMed ID: 15976883
    [No Abstract]   [Full Text] [Related]  

  • 5. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK; Dash AP
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of Kala azar.
    Singh UK
    Indian Pediatr; 1999 Mar; 36(3):231-6. PubMed ID: 10713835
    [No Abstract]   [Full Text] [Related]  

  • 8. Kala-azar: experience from a non-endemic area in India.
    Chandra J; Anand V; Patwari AK; Mandal RN; Aneja S; Sharma D
    J Trop Pediatr; 1995 Oct; 41(5):298-300. PubMed ID: 8531263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
    Thakur CP; Dedet JP; Narain S; Pratlong F
    Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 12. Kala-azar in Bihar.
    Prasad LS
    Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932
    [No Abstract]   [Full Text] [Related]  

  • 13. Changing Epidemiology: A New Focus of Kala-azar at High-Altitude Garhwal Region of North India.
    Kumar Bhat N; Ahuja V; Dhar M; Ahmad S; Pandita N; Gupta V; Chandra S
    J Trop Pediatr; 2017 Apr; 63(2):104-108. PubMed ID: 27582128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report.
    Mbui J; Rashid R; Lodenyo H; Nyakundi P; Kipmutai R; Mutuma G; Kirigi G; Kinoti D; Wasunna M
    East Afr Med J; 2003 Aug; 80(8):440-2. PubMed ID: 14601788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-emergence of visceral leishmaniasis in Gujarat, India.
    Sharma U; Redhu NS; Mathur P; Singh S
    J Vector Borne Dis; 2007 Sep; 44(3):230-2. PubMed ID: 17896628
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.
    Singh S ; Kumar J; Singh R; Dwivedi SN
    Int J Infect Dis; 2000; 4(4):203-8. PubMed ID: 11231183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
    Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
    Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK; Singh NK; Jha S
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract]   [Full Text] [Related]  

  • 19. [Visceral leishmaniasis (kala-azar): 1st case observed in Chile].
    Osorio G; Moyano C; Caravagno C; Miranda C; Ubilla M; Maturana G; Retamales I
    Rev Med Chil; 1984 Mar; 112(3):261-6. PubMed ID: 6473968
    [No Abstract]   [Full Text] [Related]  

  • 20. Visceral Leishmaniasis: Kala-azar.
    Safavi M; Eshaghi H; Hajihassani Z
    Diagn Cytopathol; 2021 Mar; 49(3):446-448. PubMed ID: 33225605
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.